Fundamental Research Articles

Text/HTML

Fundamental Articles

Lupin has acquired a Japanese pharma firm, I’rom Pharma that has a significant presence in the injectables segment, and has an annual turnover of $69 million (Rs 330 cr).

Shree Renuka Sugar posts dismal Q4 numbers

Shree Renuka Sugar posted a net loss of Rs 615 cr in Q2FY12 against net profits of 128 cr last quarter.

Tijaria Polypipes - Uncertain outlook

Tijaria Polypipes (TPL) has come up with an IPO to garner Rs 60 cr to fund its expansion program. The company’s hazy plans and lack of synergy in business activities make this an uninteresting scrip.

Hot Chips - Gandhimathi Appliances & Axis Bank

DSIJ recommendation and analysis on Gandhimathi Appliances & Axis Bank

Jubilant FoodWorks – No More Toppings

While fundamentally there is nothing wrong with JFL and its business model, all good things seem to have been priced into the valuation for now which may lead to the stock underperforming the broader market in the near to medium term.

Gujarat State Petronet - Stepping On The Gas

GSPL currently has 1874 km of pipeline, and is in a further expansion mode. The company is in the process of increasing its network in Gujarat to around 2500 km.

Tube Investments of India - Cycling To Profits

Tube Investments of India has a diversified product like that shields it from the downturns in the economy.

Indo Thai Securities - Insecure growth expectations

With subdued growth expectations from the broking business, and the scrip currently trading at higher valuations, we at DSIJ recommend investors to avoid taking any fresh positions.

ICICI Bank - Q2FY12 analysis & stock recommendation

The standalone net profit increased by 21.59% to Rs 1503 cr, while the consolidated PAT jumped 43% to Rs 1992 cr in Q2FY12

RDB Rasayans - Unrewarding Issue

RDB Rasayans brought out its IPO recently, but it was hammered down as soon as it was listed on the BSE. Even a reduced price does not discount the fact that the company’s business is fragmented and its growth inconsistent, because of which it is not likely to provide any price appreciation for investors.

Page 4 of 40

First Previous 1 2 3 [4] 5 6 7 8 9 10 Next Last